Navigation Links
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Date:3/12/2008

-Amended Agreement Accelerates Expected Timing of Final Analysis by One Year While Maintaining Comparable Powering of Interim and Final Results- -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM

ET-

SEATTLE, March 12 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) has agreed to an amended Special Protocol Assessment (SPA) for the Phase 3 IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as D9902B) clinical trial of PROVENGE(R) (sipuleucel-T), the Company's investigational active cellular immunotherapy for the treatment of advanced prostate cancer. In addition, the FDA has reconfirmed that they would accept a positive interim or final analysis from the IMPACT trial to amend the Biologics License Application (BLA) for licensure of PROVENGE.

The amended SPA accelerates the expected timing of the final IMPACT results by approximately one year while maintaining comparable powering of the study's interim and final results. By increasing the number of events and decreasing the alpha (false positive error) spending function for the interim analysis, the Company is able to reduce the number of events for the final analysis (from 360 to 304) and still maintain a comparable statistical power for both the interim and final analyses. Interim results are still expected in the second half of 2008; however, final results are now expected in the second half of 2009 rather than 2010.

Based on the statistical plan in the amended SPA, if the treatment effect at the interim analysis for the IMPACT trial is consistent with the integrated results of the previous two completed pha
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
2. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
3. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
4. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
5. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
11. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... August 29, 2014 Pittcon is pleased ... and colleague Koichiro Matsuda, Horiba Scientific, have organized a ... 5, 2014. JASIS , Asia’s largest analytical and ... in Makuhari Messe, Japan. , The four speakers ... Bioanalysis from Single Molecules to Single Cells” will present ...
(Date:8/29/2014)... 29, 2014 A major challenge before ... start-up dense realm of Boston-Cambridge, is gaining visibility that ... James Sherley, the Director of Boston’s Adult Stem Cell ... and national visibility of his company an important priority ... In addition to a social media marketing campaign ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency ... to 150 ppb,” said Mark Tess, PhD, Mycotoxin Product Manager ... plant owners and USDA-GIPSA inspection agencies that have a need ... take place in a matter of minutes with nothing but ... the feed and grain before accepting it, but they no ...
(Date:8/28/2014)... executives from clinical trial marketing firm BBK Worldwide will lead ... Clinical Trials 2014 , to be held at the Hyatt ... Patient recruitment experts Bonnie A. Brescia , Matthew ... on the benefits of employing an effective patient engagement strategy, ... mobile apps – can be used to drive study participation ...
Breaking Biology Technology:Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4BBK Worldwide Leads Sessions at Key September Events 2
... empower transplant patients ... and their ... (Pink Sheets: ALPMF), a leader in the field of transplantation, ... announced a collaborative partnership to jointly,develop further materials for the ...
... new class of anti-infectives, to ... advise Company on pexiganan development, WELLESLEY HILLS, Mass., Oct. ... following its,acquisition of rights to pexiganan, Michael Zasloff, M.D. has ... skin of the African clawed frog while at NIH (National ...
... SUNNYVALE, Calif., Oct. 16 Kyphon Inc.,(Nasdaq: KYPH ... the merger agreement with Medtronic, Inc. (NYSE: MDT ... As previously announced, on July 26, 2007, Kyphon entered ... Medtronic,agreed to acquire all of the outstanding shares of ...
Cached Biology Technology:Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 2Astellas Pharma US, Inc. and The International Transplant Nurses Society (ITNS) Collaborate on Content for Transplant Experience Program 3MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 2MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 3MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 4MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 5Kyphon Stockholders Approve Merger with Medtronic 2
(Date:8/29/2014)... news release is available in German . ... key players in the natural nitrogen cycle on Earth ... specialist bacteria were thought to depend on nitrite as ... led by Holger Daims, a microbiologist at the University ... use hydrogen as an alternative source of energy. The ...
(Date:8/29/2014)... species of marine phytoplankton, such as the prolific bloomer ... B1 (thiamine), researchers have discovered. The finding contradicts the ... other eukaryotic microbes depend on scarce supplies of thiamine ... different way to think about the ocean," says CIFAR ... The ISME Journal paper with CIFAR fellows ...
(Date:8/29/2014)... modern materials that are light, flexible and highly conductive ... electronic paper. , Making such concepts affordable enough for ... of working with copper nanowires and a PVA "nano ... in the field of ultra-lightweight "aerogel monoliths" has largely ... nanowires. , By turning instead to copper, both ...
Breaking Biology News(10 mins):Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Not all phytoplankton in the ocean need to take their vitamins 2Not all phytoplankton in the ocean need to take their vitamins 3Copper shines as flexible conductor 2
... occurring in the Sundarbans, resulting in as much as 200m ... published today (11th Jan) in Remote Sensing by ... as human development thrives, and global temperature continues to rise, ... at alarming rates. This will inevitably lead to species loss ...
... are "apple-shaped" with fat more concentrated around the abdomen ... such as heart disease and diabetes than those who are ... thighs. But new research conducted at UC Davis ... and Metabolism provides further evidence that the protective benefits ...
... Oxidative stress is a primary villain in a host ... to Alzheimer,s disease, Amyotrophic Lateral Sclerosis and Parkinson,s disease. ... Research Institute (TSRI) have found that blocking the interaction ... neurons associated with these neurodegenerative diseases, suggesting a potential ...
Cached Biology News:Bengali forests are fading away 2UC Davis study deflates notion that pear-shaped bodies more healthy than apples 2UC Davis study deflates notion that pear-shaped bodies more healthy than apples 3Scripps Florida scientists uncover potential drug target to block cell death in Parkinson's disease 2
Form: Ready to use Applications: ELISA...
EnzChek Ultra Xylanase Assay Kit *500 assays*...
Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
Defender against cell death 1...
Biology Products: